share_log

Insider Selling: BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) CEO Sells $155,970.00 in Stock

Insider Selling: BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) CEO Sells $155,970.00 in Stock

內幕銷售:生物馬林製藥公司(納斯達克:BMRN)首席執行官出售 155,970.00 美元的股票
Financial News Live ·  2022/12/09 06:22

BioMarin Pharmaceutical Inc. (NASDAQ:BMRN – Get Rating) CEO Jean Jacques Bienaime sold 1,500 shares of the business's stock in a transaction dated Friday, December 2nd. The shares were sold at an average price of $103.98, for a total transaction of $155,970.00. Following the completion of the sale, the chief executive officer now directly owns 321,424 shares of the company's stock, valued at $33,421,667.52. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website.

納斯達克首席執行官Jean Jacques Bienaime在一項日期為12月2日(星期五)的交易中出售了1,500股BioMarin製藥公司的股票。這些股票以103.98美元的平均價格出售,總成交金額為155,970.00美元。出售完成後,首席執行官現在直接擁有321,424股公司股票,價值33,421,667.52美元。這筆交易是在提交給美國證券交易委員會的一份法律文件中披露的,該文件可通過美國證券交易委員會網站.

Jean Jacques Bienaime also recently made the following trade(s):

讓·雅克·比納姆最近還進行了以下交易:

Get
到達
BioMarin Pharmaceutical
BioMarin製藥公司
alerts:
警報:
  • On Monday, October 31st, Jean Jacques Bienaime sold 1,500 shares of BioMarin Pharmaceutical stock. The stock was sold at an average price of $86.55, for a total transaction of $129,825.00.
  • On Friday, October 14th, Jean Jacques Bienaime sold 4,000 shares of BioMarin Pharmaceutical stock. The stock was sold at an average price of $89.89, for a total transaction of $359,560.00.
  • 10月31日,星期一,Jean Jacques Bienaime出售了1,500股BioMarin製藥公司的股票。該股以86.55美元的平均價格出售,總成交金額為129,825.00美元。
  • 10月14日,星期五,Jean Jacques Bienaime出售了4,000股BioMarin製藥公司的股票。該股以89.89美元的平均價格出售,總成交金額為359,560.00美元。

BioMarin Pharmaceutical Trading Up 0.7 %

BioMarin製藥公司股價上漲0.7%

Shares of BioMarin Pharmaceutical stock opened at $104.39 on Friday. The company has a current ratio of 5.15, a quick ratio of 3.54 and a debt-to-equity ratio of 0.24. BioMarin Pharmaceutical Inc. has a 12-month low of $70.73 and a 12-month high of $106.72. The firm has a market capitalization of $19.36 billion, a price-to-earnings ratio of 248.55, a PEG ratio of 2.33 and a beta of 0.37. The firm's 50 day simple moving average is $90.36 and its two-hundred day simple moving average is $87.36.

週五,BioMarin製藥公司的股票開盤報104.39美元。該公司的流動比率為5.15,速動比率為3.54,債務權益比率為0.24。BioMarin製藥公司股價跌至70.73美元的12個月低點和106.72美元的12個月高位。該公司的市值為193.6億美元,市盈率為248.55倍,聚乙二醇率為2.33倍,貝塔係數為0.37。該公司的50日簡單移動均線為90.36美元,200日簡單移動均線為87.36美元。

BioMarin Pharmaceutical (NASDAQ:BMRN – Get Rating) last issued its quarterly earnings results on Wednesday, October 26th. The biotechnology company reported $0.16 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.12 by $0.04. BioMarin Pharmaceutical had a net margin of 4.18% and a return on equity of 2.50%. The business had revenue of $505.30 million for the quarter, compared to analyst estimates of $516.03 million. During the same quarter in the prior year, the business posted ($0.03) EPS. BioMarin Pharmaceutical's revenue for the quarter was up 23.6% compared to the same quarter last year. Analysts predict that BioMarin Pharmaceutical Inc. will post 0.87 EPS for the current year.
生物醫藥公司(納斯達克代碼:BMRN-GET評級)最近一次發佈季度收益報告是在10月26日(星期三)。這家生物技術公司公佈本季度每股收益(EPS)為0.16美元,超出分析師普遍預期的0.12美元和0.04美元。BioMarin製藥公司的淨利潤率為4.18%,股本回報率為2.50%。該業務本季度營收為5.053億美元,而分析師預期為5.1603億美元。在前一年的同一季度,該業務公佈了每股收益(0.03美元)。與去年同期相比,BioMarin製藥公司本季度的收入增長了23.6%。分析師預測,BioMarin製藥公司本年度每股收益將為0.87美元。

Wall Street Analysts Forecast Growth

華爾街分析師預測經濟增長

BMRN has been the subject of several research reports. JPMorgan Chase & Co. lowered their price target on shares of BioMarin Pharmaceutical from $140.00 to $112.00 and set an "overweight" rating for the company in a research report on Monday, October 24th. Wedbush reaffirmed a "neutral" rating and issued a $74.00 price target on shares of BioMarin Pharmaceutical in a research report on Tuesday, September 13th. Evercore ISI upped their price target on shares of BioMarin Pharmaceutical to $130.00 in a research report on Friday, December 2nd. Robert W. Baird reissued an "outperform" rating and set a $112.00 target price on shares of BioMarin Pharmaceutical in a research report on Friday, August 26th. Finally, Credit Suisse Group decreased their target price on shares of BioMarin Pharmaceutical from $111.00 to $110.00 and set an "outperform" rating for the company in a research report on Thursday, October 27th. Two investment analysts have rated the stock with a hold rating and twelve have given a buy rating to the company's stock. According to data from MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and an average price target of $113.67.

BMRN已經成為幾份研究報告的主題。摩根大通將BioMarin製藥公司的股票目標價從140.00美元下調至112.00美元,並在24日(星期一)的一份研究報告中對該公司設定了“增持”評級。9月13日,週二,韋德布什在一份研究報告中重申了對BioMarin製藥公司的中性評級,並對其股票發佈了74.00美元的目標價。12月2日星期五,Evercore ISI在一份研究報告中將BioMarin製藥公司的股票目標價上調至130.00美元。8月26日,羅伯特·W·貝爾德在一份研究報告中重新發布了“跑贏大盤”的評級,併為BioMarin製藥公司的股票設定了112.00美元的目標價。最後,瑞士信貸集團將BioMarin Pharmtics的股票目標價從111.00美元下調至110.00美元,並在27日(週四)的一份研究報告中為該公司設定了“跑贏大盤”的評級。兩名投資分析師對該股的評級為持有,12名分析師對該公司股票的評級為買入。根據MarketBeat.com的數據,該股目前的普遍評級為“適度買入”,平均目標價為113.67美元。

Institutional Trading of BioMarin Pharmaceutical

BioMarin製藥公司的制度性交易

A number of hedge funds and other institutional investors have recently made changes to their positions in BMRN. Viking Global Investors LP increased its stake in shares of BioMarin Pharmaceutical by 30.7% in the first quarter. Viking Global Investors LP now owns 3,752,393 shares of the biotechnology company's stock worth $289,310,000 after acquiring an additional 882,446 shares during the period. Point72 Asset Management L.P. increased its stake in shares of BioMarin Pharmaceutical by 302.6% in the third quarter. Point72 Asset Management L.P. now owns 595,400 shares of the biotechnology company's stock worth $50,472,000 after acquiring an additional 447,529 shares during the period. Fiera Capital Corp increased its stake in shares of BioMarin Pharmaceutical by 790.9% in the first quarter. Fiera Capital Corp now owns 476,982 shares of the biotechnology company's stock worth $36,775,000 after acquiring an additional 423,444 shares during the period. Woodline Partners LP acquired a new stake in shares of BioMarin Pharmaceutical in the second quarter worth $33,411,000. Finally, Polar Capital Holdings Plc increased its stake in shares of BioMarin Pharmaceutical by 300.0% in the first quarter. Polar Capital Holdings Plc now owns 500,000 shares of the biotechnology company's stock worth $38,550,000 after acquiring an additional 375,000 shares during the period. Institutional investors and hedge funds own 94.84% of the company's stock.

一些對衝基金和其他機構投資者最近改變了他們在BMRN的頭寸。Viking Global Investors LP在第一季度增持BioMarin Pharmtics股份30.7%。Viking Global Investors LP現在擁有這家生物技術公司3752,393股股票,價值289,310,000美元,在此期間又購買了882,446股。Point72 Asset Management L.P.在第三季度增持了BioMarin製藥公司的股份,增幅為302.6%。Point72 Asset Management L.P.在此期間額外收購了447,529股,現在擁有595,400股這家生物技術公司的股票,價值50,472,000美元。菲埃拉資本公司在第一季度增持了BioMarin製藥公司的股份790.9%。Fiera Capital Corp目前持有這家生物技術公司476,982股股票,價值36,775,000美元,在此期間又購買了423,444股。Woodline Partners LP在第二季度收購了BioMarin製藥公司價值33,411,000美元的新股份。最後,極地資本控股公司在第一季度將其在BioMarin製藥公司的股份增加了300.0%。Polal Capital Holdings Plc在此期間額外收購了375,000股票,現在擁有500,000股這家生物技術公司的股票,價值38,550,000美元。機構投資者和對衝基金持有該公司94.84%的股票。

About BioMarin Pharmaceutical

關於BioMarin製藥公司

(Get Rating)

(獲取評級)

BioMarin Pharmaceutical Inc develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with MPS VI; and Kuvan, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria (PKU), an inherited metabolic disease.

BioMarin製藥公司為患有嚴重和危及生命的罕見疾病和醫療條件的人開發和銷售治療方法。它的商業產品包括Vimizim,一種治療粘多糖病IVA型溶酶體儲存障礙的酶替代療法;Naglazyme,一種用於MPS VI患者的N-乙酰半乳糖胺4-硫酸酯酶的重組形式;以及Kuvan,一種專利的6R-BH4的合成口服形式,用於治療一種遺傳性代謝性疾病苯丙酮尿症(PKU)患者。

Further Reading

進一步閲讀

  • Get a free copy of the StockNews.com research report on BioMarin Pharmaceutical (BMRN)
  • Can Pfizer, Johnson & Johnson Continue Outperforming the Index?
  • This Is Why Daktronics Fell 40% In One Day
  • Is It Time To Throw In The Towel On Gamestop?
  • Why You Should Avoid Carvana Even if it Avoids Bankruptcy
  • Are Investors Hearing The End Of Spotify's Downtrend?
  • 免費獲取StockNews.com關於BioMarin製藥公司(BMRN)的研究報告
  • 輝瑞、強生能否繼續跑贏該指數?
  • 這就是為什麼達科電子在一天內下跌了40%
  • 是時候在Gamestop上認輸了嗎?
  • 為什麼你應該避免Carvana,即使它可以避免破產
  • 投資者是否聽到了Spotify下跌趨勢的終結?

Receive News & Ratings for BioMarin Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioMarin Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.

獲得《BioMarin藥學日報》的新聞和評級-在下面輸入您的電子郵件地址,通過MarketBeat.com的免費每日電子郵件時事通訊接收對BioMarin製藥公司和相關公司的最新新聞和分析師評級的每日簡要摘要。

声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論